Navigation Links
Drug combination shrinks breast cancer metastases in brain
Date:12/17/2007

SAN ANTONIO, Texas--A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

Lapatinib (Tykerb) and capecitabine (Xeloda) were paired in an extension of a Phase 2 clinical trial in which lapatinib given alone shrank brain metastases significantly in six percent of 241 patients.

In the extension trial, capecitabine was added to lapatinib in 49 patients whose metastases -- cancerous colonies in the brain spread from their primary cancer -- had progressed while on treatment. With the combination therapy, brain metastases shrank by 20 percent or more in 18 patients (37 percent) and shrank by at least 50 percent in 10 patients (20 percent), reported Nancy Lin, MD, of Dana-Farber's Breast Oncology Center.

"Very few medications have shown activity in the treatment of brain metastases, particularly in HER-2-positive metastatic breast cancer patients," said Lin, who led the study with Eric Winer, MD, director of the Dana-Farber Breast Oncology Center. "Therefore, these data are quite encouraging, and further studies are warranted."

The data (abstract 6076) will be presented on Sunday, Dec. 16 at 7 a.m. CT.

Lapatinib is an oral small-molecule drug from GlaxoSmithKline that is approved along with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors are driven by the abnormal growth signal, HER-2, and who have already undergone therapy including trastuzumab (Herceptin), a taxane drug, and an anthracycline compound. Lapatinib, like trastuzumab, blocks the HER-2 signal.

Up to one-third of women with advanced, HER-2-positive breast cancer may develop metastases to the brain.

"Although radiation treatment is often effective, as women live long
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... Ebola vaccine appears to be safe and produces an immune ... according to early clinical trial results reported by the U.S. ... I clinical trial for the vaccine paves the way for ... and Sierra Leone as early as January, said Dr. Anthony ...
(Date:11/27/2014)... 2014 The founders of VIM & VIGR, ... high functioning compression socks, are proud to announce the debut ... innovative Gradient Pressure (TM) knitting technology that is designed to ... VIGR’s commitment to adding flair and style to a product ... caught the eye of a writer at The New ...
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... behalf of individuals who were allegedly injured by the ... court, where a federal litigation is looking ahead to ... , According to a Scheduling Order issued earlier ... take place on December 16th at 10:00 a.m. Items ...
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... IN (PRWEB) November 27, 2014 Dr. Ronald ... clinic, has a few oral health tips before patients ... who offers Louisville and New Albany affordable cosmetic dentistry, ... foods high in starch and sugar. While the staff wishes ... some helpful tips for how patients can enjoy a feast ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4
... Votes, 16-0, in Favor of Short-Term Treatment ... May 30 GlaxoSmithKline (NYSE: GSK ... and Drug Administration,s,Oncology Drugs Advisory Committee (ODAC) ... favorable risk-benefit profile for,the short-term treatment of ...
... an effective launch,team is imperative to ensuring the ... relies heavily on the success of the team ... effective, cross-functional,teams that ultimately drive sales and rapid ... report provides executives with insights into the methods,that ...
... free radicals from hypertension, study finds , , FRIDAY, May ... drug BH4 may hold promise as a treatment for people ... Currently, BH4 is used to treat a genetic disorder called ... of a molecule called phenylalanine can cause brain damage. , ...
... Premieres "You: The Exhibit" Using,Cutting-Edge Science and Medical Technology, ... years, changing your physical features in an instant, visualizing ... city around the,world without ever leaving Houston. Now, it,s ... of Health & Medical Science, also known as The,Health ...
... of product choices. Most often, there,s not just one ideal ... beer might be perfect for relaxing after work; a sports ... same as a business executive,s. , A new study in ... be accurately discovered and then used to predict the preferences ...
... to Rally Residents to Eat Right, Move More ... and Milk Their Diets, KANSAS ... and downs of different fad diets -- which seem to go in and ... out of three Americans -- including 23 percent of Kansas City,residents -- remain ...
Cached Medicine News:Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 3Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 4Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2Health News:Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement 2Health News:Nation's Only Health Museum Makes 'You' Sole Focus of New Exhibit Gallery 2Health News:Nation's Only Health Museum Makes 'You' Sole Focus of New Exhibit Gallery 3Health News:Advil or Excedrin? New model helps predict product choices 2Health News:Message to Kansas City, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Kansas City, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3
(Date:11/26/2014)... 2014 The medical magnetic resonance imaging ... 4%, with world market revenues for 2013 at ... other types of medical imaging have led to ... medical conditions in children and adults, each imaging ... Medical Imaging Markets , analyzes the current ...
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its ... Philips (NYSE: PHG AEX: PHIA) ... Drug Administration (FDA) for its IQon Spectral CT ... This first-of-its kind technology adds a new dimension to ... the ability to characterize structures based on their material ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... N.J., Dec. 22, 2011  Ikaria, Inc. announced today that ... DS drug-delivery systems related to a fretting corrosion.  This ... direction of the U.S. Food and Drug Administration (FDA).  ... a reasonable likelihood of serious adverse health consequences or ...
... 2011 ViroPharma Incorporated (NASDAQ: VPHM ) today ... acquire Meritage Pharma, Inc., a private company based in San ... a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder ... initial $7.5 million, and has agreed to provide Meritage up ...
Cached Medicine Technology:Ikaria® Issues Notice of Completed Remediation for INOMAX® DS Drug-delivery System 2Ikaria® Issues Notice of Completed Remediation for INOMAX® DS Drug-delivery System 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: